The most important cannabis-law story in the country is no longer the announcement that part of the marijuana market has been moved into Schedule III. It is the implementation phase that follows. In April 2026, the Department of Justice and the Drug Enforcement Administration took the unusual step of immediately placing state-licensed medical marijuana and certain FDA-approved marijuana products into Schedule III, while simultaneously setting a new June 29, 2026 hearing to consider broader changes to marijuana’s status under federal law.¹ The result is not full federal normalization. It is a bifurcated regime: medical cannabis now occupies a different federal posture than adult-use cannabis, and the legal consequences of that split are only beginning to surface.²
For policy researchers, lawmakers, and lawyers, the key question is no longer whether cannabis rescheduling is abstractly “coming.” The key question is what this hybrid federal move now requires of state law, state agencies, state medical programs, and regulated operators. That inquiry matters because the federal government has not moved all marijuana into Schedule III. It has instead moved a narrower category—state-licensed medical marijuana and FDA-approved marijuana products—while leaving broader marijuana policy to further proceedings.³ That choice changes the legal map immediately for medical-cannabis states, but it also sharpens the line between medical and adult-use systems in ways that many state codes were not built to handle.⁴
I. What the June 29 DEA Hearing Actually Means
The June 29 hearing matters because it is the next formal stage in a rulemaking process governed by 21 U.S.C. § 811 and DEA’s hearing regulations, not merely a public-comment spectacle.⁵ DEA has published a notice stating that the hearing will commence on June 29, 2026, at the DEA Hearing Facility in Arlington, Virginia, and conclude no later than July 15, 2026.⁶ Under the applicable regulations, hearings on the issuance, amendment, or repeal of scheduling rules are governed by the Administrative Procedure Act as well as the Controlled Substances Act and DEA’s own procedural rules.⁷ In other words, this is the stage at which the administrative record is further developed, party participation is formalized, and the rationale for any broader rule must be defended in a way that can survive judicial review.⁸
That posture matters for two reasons. First, the federal government has already created immediate legal consequences for part of the market. Second, the hearing is where the unresolved question—whether all marijuana should be moved from Schedule I to Schedule III—will now be tested through a contested administrative process.⁹ The practical effect is that federal cannabis law is now operating on two tracks at once: a present-tense partial rescheduling for medical cannabis and a future-tense broader hearing for the remainder of the marijuana classification question.¹⁰
II. What Changed Immediately
The immediate federal move did three especially important things. First, it placed qualifying medical marijuana into Schedule III.¹¹ Second, it created an expedited registration pathway for entities holding state medical marijuana licenses, allowing them to seek federal registration for manufacturing, distribution, and dispensing activity consistent with the new federal posture.¹² Third, it set up a formal medical-cannabis compliance lane that is separate from the still-unresolved status of adult-use cannabis.¹³ Reuters reported that DEA followed this with a new registration portal for medical marijuana businesses, a move that signals the federal government is trying to operationalize the narrower medical framework rather than leave it as a merely symbolic rescheduling announcement.¹⁴
One practical consequence is tax. 26 U.S.C. § 280E denies ordinary business deductions to businesses trafficking in Schedule I or Schedule II controlled substances.¹⁵ Once qualifying medical marijuana is no longer in Schedule I or II, the tax treatment question changes immediately for those operators.¹⁶ That is one reason the April 2026 order was so consequential even though it fell far short of nationwide legalization. It directly altered the federal tax posture of at least part of the cannabis industry.¹⁷
III. Why States Now Have a Conformity Problem
The federal move creates pressure on states because many state systems still speak in a pre-April-2026 vocabulary. Some states have medical programs but continue to place marijuana in Schedule I under state controlled-substances law.¹⁸ Some have already introduced bills to move marijuana to Schedule III under state law.¹⁹ Others have begun writing contingent legislation that turns on federal rescheduling as the trigger for state-level changes.²⁰ And still others are not trying to reschedule at all, but are instead asking for waivers, exceptions, or state-federal coordination measures to keep their medical systems functioning under the new federal environment.²¹
The states that matter most right now are not necessarily the ones with the loudest politics. They are the ones whose legal codes most clearly reveal the federal-state mismatch.
A. Virginia
Virginia provides one of the cleanest examples of anticipatory drafting. HB 486 expressly ties its effective date to the date on which marijuana is federally rescheduled from Schedule I to Schedule III.²² The text makes that contingency explicit, and legislative tracking reflects that the measure was incorporated into HB 75.²³ That is a sophisticated legislative response because it does not merely express support for rescheduling; it builds federal change into the trigger mechanism of state law itself.²⁴ For lawmakers elsewhere, Virginia is a model of how to draft around contingent federal developments without forcing immediate state-code revision before the federal process stabilizes.²⁵
B. West Virginia
West Virginia illustrates the opposite posture: direct scheduling reform introduced but not yet enacted. SB 809 would amend W. Va. Code §§ 60A-2-204 and 60A-2-208 to move cannabis and its natural and synthetic derivatives from Schedule I to Schedule III under state law.²⁶ The bill history shows the measure was introduced and referred to Health and Human Resources on February 6, 2026, where it appears to remain.²⁷ Existing West Virginia code still places marijuana within the state Schedule I framework, while Schedule III remains separately codified.²⁸ For policy analysts, that makes West Virginia a clean case study in unresolved state-federal divergence: a medical-cannabis state with a live rescheduling bill and a still-unreformed scheduling code.²⁹
C. Kansas
Kansas is not generally described as a model medical-cannabis state, but SB 484 is still notable because it shows that the idea of moving marijuana from Schedule I to Schedule III is not confined to the states most associated with cannabis liberalization.³⁰ The Kansas legislative page describes SB 484 as a bill “[m]oving marijuana from schedule I to schedule III of the uniform controlled substances act,” and shows it in the Senate Committee on Federal and State Affairs.³¹ The bill’s existence matters because it confirms that state scheduling conformity is now a live legislative category in its own right.³²
D. Hawaii
Hawaii is taking a different approach. Rather than simply proposing to move marijuana from one state schedule to another, HCR 170 urges the governor to “reharmonize” federal and state cannabis regulation by obtaining a controlled-substance exception for registered medical cannabis patients and registration waivers for state-licensed medical cannabis dispensaries from DEA.³³ That resolution matters because Hawaii already has a detailed medical-cannabis framework under Haw. Rev. Stat. ch. 329D, including licensed dispensaries and an explicit statutory provision on coordination among state and federal agencies.³⁴ Hawaii is therefore not just confronting the abstract legality of cannabis; it is confronting the practical problem of how a functioning medical system interfaces with newly shifting federal rules.³⁵
IV. Why This Is More Than a Cannabis Story
There is also a structural lesson here that extends beyond cannabis. In Connecticut, Governor Ned Lamont signed HB 5044 on April 27, 2026, revising the state’s RFRA so that school immunization requirements are excluded from its protection in response to pending litigation.³⁶ That bill is not a cannabis law, but it illustrates the same governance problem from another angle: when a live statutory regime begins doing real work in litigation, legislatures often respond by rewriting the governing framework itself.³⁷ In cannabis, that can mean rewriting schedules, tax provisions, or medical-program interfaces; in RFRA disputes, it can mean rewriting the substantive reach of the religious-liberty statute itself.³⁸ For lawmakers, the common lesson is that implementation pressure is where legal abstractions become institutional choices.³⁹
V. What States May Have to Change Next
The states most affected by the federal move will now have to inventory at least five categories of law and administration.
First, they will need to evaluate their controlled-substances schedules and determine whether a state medical program can continue to coexist with a state Schedule I classification without inviting litigation, contradiction, or legislative pressure.⁴⁰
Second, they will need to revisit tax treatment and any state-law provisions that track federal classification or rely on pre-rescheduling assumptions.⁴¹
Third, they will need to examine licensure and registration pathways, especially if operators seek to use DEA’s new medical registration process while remaining compliant with state licensure rules.⁴²
Fourth, they will need to clarify the legal status of medical facilities, dispensaries, patients, and caregivers under statutes that were drafted when federal law treated all marijuana the same.⁴³
Fifth, they will need a plan for state-federal coordination, because a medical program that is legal under state law but only partially normalized under federal law will generate questions about privacy, data-sharing, registration, transportation, and enforcement priorities.⁴⁴ Hawaii’s statutory coordination language is a useful example of what such a framework can look like.⁴⁵
VI. What to Watch Next
Between now and the June 29 hearing, the biggest things to watch are:
1. Whether DEA’s pre-hearing process expands or narrows the categories under consideration. The June hearing is the formal site where broader rescheduling will be litigated within the agency process.⁴⁶
2. Whether more states follow Virginia’s contingent-trigger model or West Virginia/Kansas’s direct-rescheduling model. Those are two very different legislative strategies, and each signals a different level of confidence about how durable the federal shift will be.⁴⁷
3. Whether medical-cannabis operators can meaningfully use DEA’s new registration portal. If the portal becomes a real pathway rather than a symbolic one, it will deepen the split between federally tolerated medical systems and still-unresolved adult-use systems.⁴⁸
4. Whether state medical-program statutes need technical amendments even where no rescheduling bill is filed. A state does not have to enact a headline-grabbing Schedule III bill to face real conformity pressure.⁴⁹
5. Whether federal tax treatment becomes the dominant implementation issue. For many regulated operators, the practical significance of the April move may be felt first through tax reporting rather than criminal enforcement.⁵⁰
Conclusion
The headline phase of rescheduling is over. The harder phase has begun. The federal government has created a medical-cannabis Schedule III category, opened a corresponding registration pathway, and set a hearing to decide what comes next.⁵¹ States now face a choice: conform directly, draft contingently, seek waivers and coordination, or sit in open contradiction while their medical programs continue to operate under increasingly unstable legal assumptions.⁵² For policy researchers, lawmakers, and lawyers, the immediate task is not to debate whether rescheduling is historically significant. It is to identify where the new federal posture collides with existing state law—and which institutions will move first to resolve that collision.⁵³
Footnotes
¹ 21 U.S.C. § 811(a) (2024).
² Press Release, U.S. Dep’t of Just., Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-Issued License in Schedule III (Apr. 24, 2026).
³ Schedules of Controlled Substances: Rescheduling of Marijuana, 91 Fed. Reg. ___ (Apr. 28, 2026) (notice of hearing setting June 29, 2026 hearing).
⁴ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License, 91 Fed. Reg. ___ (Apr. 28, 2026).
⁵ 21 U.S.C. § 811(a)–(b) (2024).
⁶ Schedules of Controlled Substances: Rescheduling of Marijuana, supra note 3.
⁷ 21 C.F.R. § 1308.41 (2026).
⁸ 5 U.S.C. §§ 551–559 (2024); 21 C.F.R. §§ 1308.42–1308.51 (2026).
⁹ Press Release, U.S. Dep’t of Just., supra note 2.
¹⁰ Schedules of Controlled Substances: Rescheduling of Marijuana, supra note 3.
¹¹ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License, supra note 4.
¹² Id.
¹³ Id.
¹⁴ Luc Cohen, U.S. DEA Medical Marijuana Registration Portal to Launch Wednesday, Reuters (Apr. 27, 2026).
¹⁵ 26 U.S.C. § 280E (2024).
¹⁶ Id.
¹⁷ AP, Trump Reclassifies State-Licensed Medical Marijuana as a Less-Dangerous Drug in a Historic Shift (Apr. 2026).
¹⁸ W. Va. Code § 60A-2-204 (2026).
¹⁹ S.B. 809, 2026 Reg. Sess. (W. Va. 2026); S.B. 484, 2026 Reg. Sess. (Kan. 2026).
²⁰ H.B. 486, 2026 Reg. Sess. (Va. 2026).
²¹ H.C.R. 170, 33d Leg., Reg. Sess. (Haw. 2026).
²² H.B. 486, 2026 Reg. Sess. (Va. 2026) (“That the provisions of this act shall become effective upon the date that marijuana is federally rescheduled from Schedule I to Schedule III …”).
²³ Virginia Legislative Info. Sys., HB 486 Bill Details (2026); see also H.B. 75, 2026 Reg. Sess. (Va. 2026) (incorporating H.B. 486).
²⁴ H.B. 486, supra note 22.
²⁵ Id.
²⁶ S.B. 809, 2026 Reg. Sess. (W. Va. 2026).
²⁷ West Virginia Legislature, Bill Status—S.B. 809 (2026).
²⁸ W. Va. Code §§ 60A-2-204, -208 (2026).
²⁹ Id.; see also S.B. 809, supra note 26.
³⁰ S.B. 484, 2026 Reg. Sess. (Kan. 2026).
³¹ Kansas Legislature, S.B. 484 Bill Page (2026).
³² Id.
³³ H.C.R. 170, 33d Leg., Reg. Sess. (Haw. 2026).
³⁴ Haw. Rev. Stat. §§ 329D-1 to -27 (2025).
³⁵ Haw. Rev. Stat. § 329D-25 (2025).
³⁶ H.B. 5044, 2026 Gen. Assemb., Feb. Sess. (Conn. 2026); Governor Ned Lamont, Press Release, Governor Lamont Signs Legislation Protecting Vaccine Access Amid Federal Public Health Rollbacks (Apr. 27, 2026).
³⁷ Spillane v. Lamont, 368 Conn. ___, No. SC 20776 (2024).
³⁸ H.B. 5044, supra note 36.
³⁹ Id.; Spillane, supra note 37.
⁴⁰ See, e.g., W. Va. Code §§ 60A-2-204, -208 (2026); S.B. 809, supra note 26; S.B. 484, supra note 30.
⁴¹ 26 U.S.C. § 280E (2024).
⁴² Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License, supra note 4; Cohen, supra note 14.
⁴³ H.B. 486, supra note 22; Haw. Rev. Stat. ch. 329D (2025).
⁴⁴ Haw. Rev. Stat. § 329D-25 (2025).
⁴⁵ Id.
⁴⁶ Schedules of Controlled Substances: Rescheduling of Marijuana, supra note 3.
⁴⁷ Compare H.B. 486, supra note 22, with S.B. 809, supra note 26, and S.B. 484, supra note 30.
⁴⁸ Cohen, supra note 14.
⁴⁹ H.C.R. 170, supra note 33; Haw. Rev. Stat. § 329D-25 (2025).
⁵⁰ 26 U.S.C. § 280E (2024).
⁵¹ Press Release, U.S. Dep’t of Just., supra note 2; Schedules of Controlled Substances: Rescheduling of Marijuana, supra note 3; Cohen, supra note 14.
⁵² Compare H.B. 486, supra note 22, with S.B. 809, supra note 26, S.B. 484, supra note 30, and H.C.R. 170, supra note 33.
⁵³ Id.
WeedPress: The Paper Trail 
Leave a comment